Nova Minerals (Nasdaq: NVA) has kicked off preparations for a major 15,000m drill campaign at its flagship Estelle Project in Alaska’s Tintina Gold Belt. The program targets resource expansion at RPM and Korbel, while fast-tracking a maiden gold-antimony resource at the high-grade Stibium prospect—where samples have shown up to 141 g/t Au and 60.5% Sb. With gold and antimony near record highs and potential U.S. defense funding in play, Nova is positioning to unlock significant value across this 500km² critical minerals asset.

Venu Holding Corporation (NYSE American: VENU), a rising force in premium live entertainment and hospitality, will be added to the Russell 3000® Index after market close on June 27, 2025. The inclusion marks a key milestone as VENU scales its innovative, asset-light model—with 11 new venues in development, $200M in projected Luxe FireSuite sales, and expected gross ticket receipts topping $1.5B annually—positioning the company as a disruptive leader in a high-growth, multi-billion-dollar market.

Fathom Realty, a subsidiary of Fathom Holdings (Nasdaq: FTHM), has been named one of U.S. News & World Report’s 2025–2026 Best Companies to Work For, reflecting top-tier scores in safety, compensation, culture, and career development. This third-party validation affirms the strength of Fathom’s disruptive flat-fee brokerage model and tech-driven platform, which has attracted over 14,700 agents across 43 states and delivered 32% year-over-year revenue growth in Q1 2025. As the company continues to scale with low overhead, integrated services, and high-margin potential, its commitment to agent satisfaction is proving to be a key driver of sustainable value creation.

Processa Pharmaceuticals (Nasdaq: PCSA) announced three key abstracts accepted at the 2025 ASCO Annual Meeting, highlighting progress on its Next Generation Cancer (NGC) pipeline. Featured data includes a Phase 2 adaptive trial in metastatic breast cancer with PCS6422 + capecitabine (NGC-Cap), as well as preclinical insights into PCS11T (NGC-Iri), a tumor-targeted SN-38 prodrug. These updates reinforce Processa’s Regulatory Science-driven strategy to deliver safer, more effective cancer treatments with optimized dosing and improved therapeutic windows.